Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MediciNova, Inc.

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
From MediciNova, Inc.
Via GlobeNewswire
Tickers MNOV
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS